Aurinia Pharmaceuticals Inc. (AUPH) Form 8-K — Oct 30, 2026
Aurinia Pharmaceuticals reported Q3 2026 total revenue of $83.7 million, up 14% year-over-year, with LUPKYNIS net product sales of $79.4 million (+12%). Net income was $31.7 million ($0.23 diluted EPS) and nine-month net income rose 35% to $103.5 million, with cash and investments of $486.9 million at quarter end. Management raised 2026 total revenue guidance to $325-330 million (from $315-325 million) and narrowed net product sales guidance to $310-315 million.
Key figures
- Eps
- 0.23
- Revenue
- 83700000
- Guidance
- 2026 total revenue guidance raised from $315-325M to $325-330M; net product sales guidance narrowed from $305-315M to $310-315M
- Net Income
- 31700000
- Revenue Yoy
- 14%
- Cash Position
- 486900000
- Shares Outstanding
- 133995000
- Nine month net income
- $103.5M (+35% YoY)
- Nine month diluted eps
- $0.76 (+38% YoY)
- Share repurchases 2026
- 5.0M shares for $74.9M
- Nine month total revenue
- $244.6M (+19% YoY)
- License royalty revenue q3
- $4.3M (+54% YoY)
- Q3 net product sales lupkynis
- $79.4M (+12% YoY)
- Operating cash flow nine months
- $131.5M (+46% YoY)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.